NCT04742075View on ClinicalTrials.gov

Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions
Ovarian Cancer
Interventions
DRUG

Olaparib + durvalumab + UV1

The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.

Trial Locations (1)

2100

RECRUITING

Rigshospitalet, København Ø

All Listed Sponsors
collaborator

North Eastern German Society of Gynaecological Oncology

OTHER

collaborator

Belgian Gynaecological Oncology Group

OTHER

collaborator

Hellenic Cooperative Oncology Group (HeCOG)

UNKNOWN

collaborator

Arbeitsgemeinschaft Gynaekologische Onkologie Austria (AGO-Austria)

UNKNOWN

collaborator

European Network of Gynaecological Oncological Trial Groups (ENGOT)

OTHER

collaborator

Dutch Gynaecological Oncology Group

OTHER

lead

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

OTHER